BiondVax Selected as part of OCS/IATI Delegation to 2015 BIO International Convention in Philadelphia

Nes Ziona, Israel, June 10, 2015 – BiondVax Pharmaceuticals Ltd. (TASE: BNDX, Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced that it was seleted to participdate in the 2015 BIO International Convention, which is being held from June 15-18 in Philadelphia, Pennsylvania.Biondvax was selected to be a part of the Israeli delegation, together with some of the other leading and most promising biotech companies in Israel, and is attending under the auspices of the Office of the Chief Scientist in Israel (OCS). The OCS has supported BiondVax’s research, pre-clinical and clinical development by awarding the Company with substantial research funds for the past 6 years.Dr. Hassin, BiondVax’s Chief Operating officer (COO) will discuss BiondVax’s achievements. Dr Hassin will take the opportunity of meeting with potential CMOs to discuss collaboration for technology transfer and large scale production of phase 3 and commercial batches of Biondvax’s M-001 universal flu vaccine.Commented Dr. Ron Babecoff, CEO of Biondvax, “We are pleased with the validation given to us by the Office of the Chief Scientist in Israel, selecting us amongst a unique group to represent Israeli biotech innovation at the major BIO international convention in the United States. In particular, given the recent widespread Bird Flu outbreak in the United States, our solution is very relevent at the show this year where the spotlight has been put on the need for an efficient broad-coverage vaccine.” Dr. Shimon Hassin, BiondVax's COO, said, "In order to be ready for the phase 3 and the market we need to partner with a leading CMO for the production of our universal flu vaccine on a large scale. The meetings scheduled during the BIO and beyond, are of utmost importance for selection of our manufacturing partner."